FDA Approves Cinqair To Treat Severe Asthma – Pharmacy Practice News


Medscape

FDA Approves Cinqair To Treat Severe Asthma
Pharmacy Practice News
The FDA has approved reslizumab (Cinqair, Teva Pharmaceuticals) as an add-on maintenance treatment for patients aged 18 years and older with an eosinophilic phenotype asthma, who have a history of severe exacerbations despite receiving their current …
FDA approves reslizumab to treat severe asthmaPharmacy Today, American Pharmacists Association, pharmacist.com
Reslizumab (Cinqair) Approved to Treat Severe AsthmaMedscape
Cinqair Receives FDA Approval As Treatment For Severe AsthmaTech Times
Healio –Globes
all 61 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.